Megalomicin Inhibits HIV-1 Replication and Interferes with gp160 Processing  by José, Ester San et al.
VIROLOGY 239, 303–314 (1997)
ARTICLE NO. VY978872
Megalomicin Inhibits HIV-1 Replication and Interferes with gp160 Processing
Ester San Jose´,* M. Angeles Mun˜oz-Ferna´ndez,† and Balbino Alarco´n*,1
*Centro de BiologıB a Molecular Severo Ochoa, CSIC-UAM, Universidad Auto´noma de Madrid, 28049 Madrid, Spain; and the
†Department of Immunology, Gregorio Maran˜o´n Universitary Hospital, Madrid, Spain
Received June 2, 1997; returned to author for revision August 5, 1997; accepted September 30, 1997
The inhibitory effects on HIV replication of megalomicin (MGM), an inhibitor of intra-Golgi vesicle transport, have been
studied. In experiments at low multiplicity of infection on Jurkat and MT2 cell lines, MGM inhibited the production of p24
antigen, the formation of syncytia, and the induction of apoptosis at concentrations below 5 mM. Furthermore, PCR analysis
of genomic DNA showed that, in the presence of MGM, HIV-1 had been eradicated from the culture. MGM also inhibited
replication of primary isolates of HIV-1 in blood lymphoblasts and more importantly, at 1 mM, MGM inhibited depletion of
CD4/ T cells in cultures of blood lymphocytes from seropositive patients. Finally, MGM inhibited the generation of infectious
virions and the processing of the envelope protein precursor gp160 to its mature forms, resulting in the rapid degradation
of gp160. These data suggest that MGM induces a powerful inhibitory effect on HIV-1 replication at nontoxic concentrations
by preventing the processing of HIV-1 gp160 envelope protein and the subsequent formation of infectious viral particles.
q 1997 Academic Press
INTRODUCTION nospermine and deoxynojirimycin (Gruters et al., 1987;
Pal et al., 1989; Shimizu et al., 1990; Sunkara et al., 1987),
The development of inhibitors of cellular pathways that
which caused alterations in the processing of gp160 to
are essential for the replicative cycle of HIV could be of
gp120 and gp41 or alterations in the binding of gp120 to
interest because treatment with such drugs would not
CD4. However, these inhibitors were too toxic to cells tolikely result in the development of drug-resistant viral
be considered for clinical trials. More promising resultsstrains commonly found for inhibitors of viral encoded
were obtained with the derivative N-butyl deoxynojiri-enzymes (Collier et al., 1996; Jacobsen et al., 1996). Gly-
mycin, which inhibited viral replication at doses well be-cosylation inhibitors have been previously investigated
low cytotoxicity (Karpas et al., 1988; Fleet et al., 1988).as possible anti-HIV therapeutic agents (Reviewed by
Another type of inhibitor, monensin, a sodium ionophoreRatner, 1992). The envelope glycoprotein of HIV is syn-
that inhibits intracellular transport through the ER andthesized in the endoplasmic reticulum (ER) as a precur-
Golgi, blocked proteolytic processing of gp160 and inhib-sor of 160 kDa, named gp160, which is transported to
ited formation of syncytia (Dewar et al., 1989).the cell surface via the Golgi apparatus. In the Golgi,
Megalomicin (MGM) is a wide spectrum antibacterialgp160 is proteolytically processed into two subunits,
macrolide antibiotic that, as we have previously showngp120 and gp41, that remain associated and constitute
(Alarco´n et al., 1984, 1988), has a good antiviral activitythe mature viral receptor. The fusion of the virus with the
against enveloped viruses such as herpes simplex (HSV),host cell membrane requires the proteolytic cleavage of
Semliki Forest virus, and vesicular stomatitis virus,gp160 to gp120 and gp41, since noncleavable mutants
whereas it was inactive against naked viruses such asare devoid of both membrane fusion activity and func-
polio and encefalomiocarditis viruses. The study of itstional virus release (Guo et al., 1990; McCune et al.,
mechanism of action showed that MGM inhibited the1988).
last steps in the glycosylation of HSV glycoproteins (Alar-In addition to proteolytic processing, the modifications
co´n et al., 1988). More recently, we have shown thatof oligosaccharides that begin in the ER continue in the
MGM causes a dilation of the transcisternae of the GolgiGolgi by a number of glucosidases, mannosidases, and
apparatus whereas the cis and medial cisternae ap-sugar transferases that finally convert gp120 and gp41
peared normal or slightly distorted (Bonay et al., 1996).to mature glycoproteins (Ratner, 1992). Several glycosyla-
Biochemical studies showed that, in the presence oftion inhibitors have been shown to have anti-HIV activity,
MGM, glycoproteins were normally modified up to theincluding the glucosidases I and II inhibitors casta-
steps that take place before the trans-Golgi but were
defectively sialylated. These data were consistent with1 To whom correspondence and reprint requests should be ad-
dressed. Fax: 34-1-3978087. an inhibition of protein transport beyond the medial-
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Golgi. Indeed, in an in vitro system, it was shown that syncytia were observed in the culture. The cells were
then pelleted at 1200 rpm for 10 min, the supernatantMGM actually inhibited vesicular transport between the
medial- and trans-Golgi (Bonay et al., 1996). was titrated, and the cells were lysed and used as posi-
tive control in the subsequent experiments. The primaryWe show here that MGM strongly inhibits the replica-
tion of HIV in the human T cell leukemic lines Jurkat and HIV-1 T-tropic isolate 1990 was obtained by us from a
HIV-1 seropositive patient, expanded once by in vitroMT2, preventing formation of syncytia, production of p24
antigen, and induction of apoptosis. Furthermore, MGM infection of normal donor lymphoblasts, and titrated.
was active against clinical isolates of HIV, preventing
Infection assaysapoptosis of CD4/ PHA-stimulated lymphoblasts from
HIV-infected donors. The anti-HV activity of MGM seems Jurkat and MT2 cells were exposed to HIV-1, at differ-
to be based on the inhibition of processing of gp160 to ent m.o.i. (0.01 or 2.5, depending on the experiment), for
gp120 and gp41, resulting in the production of noninfec- 2 h at 377. The cells were then washed and propagated
tious virions. in complete medium with or without MGM at different
concentrations and for different periods of time. Viral rep-
MATERIALS AND METHODS lication was monitored each 3–4 days by measuring viral
p24 antigen in the supernatant of the cultures with anDrug
antigen capture immunoassay (ELAVIA Ag, Pasteur Diag-
MGM was obtained from cultures of Micromonospora nostics, Paris, France) and by formation of syncytia.
megalomicea (ATCC 27598) by a procedure described
in Bonay et al. (1996) and Weinstein et al. (1972). PCR
Some HIV-infected cells were treated with 50 mMCell cultures
MGM or left untreated and collected at days 7 and 14 for
The CD4/ T-lymphoblastic cell line Jurkat and the genomic DNA extraction according to the manufacturer’s
HTLV-1 transformed cell line MT-2 were obtained from specifications (Linus, Cultek, Madrid, Spain). Sequences
The American Type Culture Collection. The cells were containing the HIV-1 env gene were amplified by nested
maintained in RPMI 1640 plus 5% heat-inactivated fetal PCR using primer pairs which recognize gp41. The outer
bovine serum (FBS). HeLa CD4/ cells, a CD4-transfected primers were as follows: JA13, 5*-TTCCTTGGGTTCTTG-
human cervical carcinoma line, (Chesebro and Wehrly, GGAGC (nucleotides 8004–8023) and JA16, 5*-AGGTAT-
1988), were grown in DME medium supplemented with CTTTCCACAGCCAG (nucleotides 8209–8190). The inner
5% FBS. Peripheral blood mononuclear cells (PBMC) primers were as follows: JA14, 5*-GCAGCAGGAAGC-
from HIV-1-seropositive individuals (tested by Western ACTATGGG (nucleotides 8022–8041) and JA15, 5* CCA-
blot analysis and detection of p24 in plasma) with a CD4/ GGACTCTTGCCTGGAGC (nucleotides 8194–8175). For
cell count of 22% were isolated from whole blood by each sample, 1 to 2 mg of template DNA was added to
Ficoll Hypaque (Pharmacia Fine Chemicals, Uppsala, a PCR mixture (7 mM MgCl2 , 200 mM concentrations of
Sweden) centrifugation and resuspended in RPMI/ 10% each deoxynucleoside triphosphate, 12.5 pmol of each
FBS as above with phytohemagglutinin P (PHA) (Sigma outer primer, and 5 U of Taq DNA polymerase) in a final
Chemical Co., St. Louis, MO) (1 mg/ml) for 2 days. The volume of 50 ml. Amplification was carried out for 24
cultures were then propagated in medium supplemented cycles (957 for 20 s, 457 for 20 s, 727 for 20 s, with an
with 20 U/ml of recombinant human IL-2 (Boehringer additional 2 s in each cycle). An aliquot of 5 ml from the
Mannheim Biochemica, Mannheim, Germany). first-round PCR was then transferred to a new reaction
mixture containing the inner primer pair, and the second
Viral preparations round of amplification was performed for 24 additional
cycles under the same conditions (Mun˜oz-Ferna´ndez etHigh-titer stocks of HIV-1 S61p2 strain (kindly provided
al., 1996).by Dr. C. Lo´pez-GalıB ndez, Instituto Carlos III, Madrid,
Spain) (Sa´nchez-Palomino et al., 1993) and pNL strain
Detection of apoptosis
(kindly provided by Dr. J. AlcamıB , Hospital Doce de Octu-
bre, Madrid, Spain) (Adachi et al., 1986) were prepared Approximately 5 1 105 cells were collected, washed,
and resuspended in a buffer containing 0.1% sodium ci-and titrated using the end point dilution method of Ka¨rber
(1931). Briefly, 106 MT-2 cells were infected with the cor- trate, 0.3% NP-40, 50 mg/ml propidium iodide (Sigma
Chemical Co., St. Louis, MO), and 20 mg/ml RNase Aresponding virus at a multiplicity of infection (m.o.i.) of
0.1 in a final volume of 5 ml of complete medium. After (Boehringer Mannheim). After 20 min at room tempera-
ture, the cells were fixed with 1% paraformaldehyde and3–4 days, when the cells presented a 75% of syncytia,
30 1 106 MT-2 cells in 30 ml of complete medium were were analyzed in an XL flow cytometer (Coulter Eurodiag-
nostics, Krefeld, Germany). Apoptotic nuclei were visual-added to the culture and incubated again until 75% of
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ized in a Zeiss Axioskop fluorescence microscope after diluted with 4.5 ml of complete RPMI and an aliquot was
taken at that time as chase 0; the remaining samplesstaining with Hoechst 33258 (Sigma) for 7 min on ice.
were incubated at 377 and further aliquots were taken at
Analysis of cell surface CD4 expression times 2, 4, and 6 h of chase. The cells were lysed in 1%
NP-40 lysis buffer (1% NP-40, 140 mM NaCl, 20 mM Tris–PBMC isolated from HIV-1 seropositive individuals
HCl, pH 7.8, 10 mM iodoacetamide, 1 mM PMSF, and 1were cultured with different concentrations of MGM for
mg/ml each of leupeptin and aprotinin) and the lysateseveral days. For phenotypic analysis, 5 1 105 cells were
was centrifuged at 12,000 g for 15 min to remove nucleiwashed in phosphate-buffered saline (PBS) and incu-
and cell debris. The supernatants were precleared andbated for 30 min on ice with FITC-conjugated anti-CD4
subjected to immunoprecipitation with human anti-HIV-antibody Leu 3a (Becton Dickinson, Immunocytometry
1 antiserum obtained from a seropositive donor. Immuno-Systems, San Jose´, CA). The samples were fixed with 1%
precipitation and sodium dodecyl sulfate– polyacryl-paraformaldehyde in PBS and analyzed by flow cytometry
amide gel electrophoresis (SDS–PAGE) were performed(Navarro et al., 1996).
as previously described (Alarco´n et al., 1991). The 35S-
labeled protein bands were visualized and quantitatedWestern blot analysis of gp160/gp120
in a Fujix BAS1000 PhosphorImager (Fuji Photo Film,
To evaluate the processing of the HIV-1 envelope pro- Kanagawa, Japan).
tein in the presence of MGM, total protein extracts were
prepared from cells infected at high multiplicity (2.5 infec- Immunofluorescence staining
tious units/cell) and treated with different concentrations
HeLa CD4/ cells were seeded on coverslips in a p24of MGM. Cells were collected 48 h postinfection and
plate at 5 1 104 cells/well. After 24 h the cells werelysed in 500 ml of NP-40 lysis buffer containing 1% NP-
infected at a m.o.i. of 1 during 2 h at 377. The cells40, 150 mM NaCl, 20 mM Tris–HCl, pH 7.8, 10 mM iodo-
were then washed twice with PBS and incubated withacetamide, 1 mM phenylmethylsulfonyl fluoride (PMSF),
complete medium in the presence of MGM (30 mM) or1 mg/ml aprotinin, and 1 mg/ml leupeptin. After incubation
without MGM during 48 h. Cell monolayers were thenfor 30 min on ice, the cell lysates were centrifuged at
washed twice with PBS, fixed for 20 min with 2% para-12,000 g for 15 min to eliminate nuclei and cell debris.
formaldehyde (Merck, Darmstadt, Germany) in PBS atThe supernatants were transferred to another tube con-
room temperature, and permeabilized by incubation withtaining 500 ml of acetone and incubated for 30 min on ice.
1% bovine serum albumin (BSA) (Sigma) and 0.1% sapo-The samples were subsequently centrifuged at 12,000 g
nin (Sigma) in PBS for 1 h at room temperature. After thisfor 15 min and the pellets were resuspended in 100 ml
step the coverslips were incubated for 60 min upside-of Laemmli loading buffer. Equal amounts (correspond-
down on a drop of a 1/100 anti-gp160/120 solution or anti-ing to 3 1 105 cells) of all protein samples were loaded
galactosyl transferase (kindly given by Dr. Eric Bergeronto 7–17% gradient polyacrylamide gels. Proteins were
University of Zu¨rich (Berger et al., 1986), dilution 1/200).transferred to nitrocellulose filters by using a Trans-Blot
The coverslips were extensively washed with PBS andCell apparatus (Bio-Rad) for 2 h at 400 mA. Filters were
incubated on a drop of the second fluoresceinated orincubated in blocking solution (10% nonfat dry milk in
Texas red labeled antibody (Southern Biotechnology As-PBS) for 1 h at room temperature and then were hybrid-
sociates, Inc., Birmingham, AL, dilution 1/100). Finally,ized for 1 h with a 1:100 dilution of a monoclonal anti-
the coverslips were extensively washed with PBS andgp160/gp120 antibody (Du Pont de Nemours, Dreieich,
mounted on slides with a Mowiol solution prepared asGermany) in PBS plus 0.1% Tween 20 (PBS/Tween). The
described (Heimer and Taylor, 1974). The preparationsfilters were washed five times with 100 ml of PBS/Tween
were examined with a Zeiss Axioscop microscope andand were incubated for 1 h with a peroxidase-conjugated
photographed on Kodak TMAX 400 film.sheep anti-mouse Ig antibody (Amersham, UK). The fil-
ters were washed five times with 100 ml of PBS/Tween
and ECL was performed according to the manufacturer’s RESULTS
specifications (Amersham).
Effect of MGM on HIV-1 replication
Metabolic labeling
Because MGM had proven activity against enveloped
viruses (Alarco´n et al., 1984, 1988) it was compelling toFor metabolic labeling, 6 1 106 MT2 cells were in-
fected with the pNL isolate at a m.o.i. of 2 and half of test its possible anti-HIV activity. To this aim, Jurkat cells
were infected with HIV-1 (isolate S61p2) at a m.o.i. ofthem were treated with 50 mM MGM. Forty-eight hours
later both MGM-treated and untreated cells were labeled 0.01 and the release of viral p24 antigen to the culture
medium was followed for 18 days postinfection. Aswith 1 mCi [35S]methionine (Amersham, UK) for 1 h in 1.5
ml of methionine-free medium. The medium was then shown in Fig. 1A, 50 mM MGM inhibited by more than
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FIG. 1. Inhibition of HIV replication in T lymphoblastoid lines by MGM. (A) Time course of viral p24 antigen release in HIV-1 infected cells. Jurkat
cells were infected with the S61p2 isolate at a m.o.i. of 0.01 in the presence of 0 (open circles), 5 mM (closed circles), or 50 mM (closed squares)
MGM, and p24 release was measured in the culture supernatant along infection. (B) Dose–response effect of MGM on p24 release by Jurkat and
MT2 cells infected with the S61p2 isolate. (C) Detection of integrated HIV-1 proviruses in MGM-treated cells. PCR was performed to amplify a
portion of the env gene from genomic DNA extracted from HIV-1 infected Jurkat cells. Lane 1, negative control, without template; lane 2, untreated
cells, day 7; lane 3, untreated cells, day 14; lane 4, cells treated with 30 mM MGM, day 7; lane 5, cells treated with 30 mM MGM, day 14; lane 6,
positive control, plasmid psp64.
99% the production of p24 at days 14 and 18 (22 vs 2785 since the HIV genome was undetectable by PCR 14 days
after infection (Fig. 1C). Therefore, it seems that MGMpg/ml at day 18). However, a 10-fold lower concentration
of MGM, 5 mM, did not have any detectable effect on treatment resulted in the final elimination of HIV.
Induction of apoptosis is a prominent feature duringp24. Intermediate concentrations of MGM were then as-
sayed in a similar experiment on infected Jurkat and MT2 HIV infection. Apparently it can result from direct infec-
tion, but also, CD4/ uninfected cells appear to undergocells. As shown in Fig. 1B, 15 mM MGM blocked p24
production in infected Jurkat cells although at 5 mM, increased apoptosis in HIV-asymptomatic patients. It has
been shown that the interaction of gp120 with CD4 inMGM was, again, inactive. There seems to be a cell
host effect because 5 mM MGM completely inhibited p24 noninfected cells may induce apoptosis and this can be
a major mechanism of depletion of CD4/ T lymphocytes.production in infected MT2 cells (0 vs 5924 pg/ml) (Fig.
1B). In addition, at 5 mM, MGM totally prevented the The effect of MGM on HIV-induced apoptosis was ana-
lyzed in Jurkat cells infected with isolate S61p2 at a multi-formation of syncytia by MT2-infected cells (data not
shown). The inhibition by MGM of HIV replication did not plicity of 0.01. At day 14, cells were collected and the
cell cycle was analyzed by propidium iodide staining. Asresult in the permanence of the virus in a latent state
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a maximum of 53% when cultured with 30 mM MGM.
Because in the presence of MGM the percentage of
CD4/ cells increased well above the initial value, this
would suggest that MGM is able to protect them from
apoptosis. Indeed, as shown in Fig. 3C, MGM reduced
the number of cells in apoptosis from 24% in the un-
treated sample to 11% in cells treated with 25 mM MGM.FIG. 1—Continued
These data show that MGM inhibits the replication of
primary isolates of HIV-1 as well as the cytotoxic effects
of HIV on CD4/ T cells from the blood of seropositiveshown in Fig. 2A, 36% of cells from the infected, untreated
donors at concentrations as low as 1 mM, suggestingsample were undergoing apoptosis as indicated by their
that MGM is active against clinical isolates of the virus.sub-G1 content of DNA. By contrast, in the presence of
50 mM MGM the percentage of cells in apoptosis was
reduced to 7%, close to the background level of unin- Inhibition of HIV-1 envelope protein maturation
fected cells (5%). Interestingly, MGM considerably re- by MGM
duced the percentage of Jurkat cells in apoptosis at 5mM,
Since the above experiments had been performed ata concentration that did not have any detectable effect
low multiplicity of infection, we could not determine theon p24 production in this cell line (Fig. 1). In addition
stage of the viral replicative cycle being inhibited byto cell cycle analysis, apoptosis of infected cells was
MGM. Since we had previously shown that MGM inhib-examined by fluorescence microscopy of samples
ited vesicular transport from the medial to the trans sidestained with the DNA-binding dye Hoescht 33258. As
of the Golgi (Bonay et al., 1996), it could be anticipatedshown in Fig. 2B, in infected untreated samples most
that MGM would affect the processing and maturationcells had fragmented nuclei, whereas in the presence of
of the viral envelope protein. To investigate this point,50 mM MGM most cells had their nuclei intact, sug-
MT2 cells were infected with HIV-1 (pNL isolate) at 2.5gesting that MGM protects them from HIV-induced
m.o.i. MGM was added 2 h after the infection and theapoptosis.
synthesis of viral envelope proteins was examined 24
and 48 h later by Western blotting with a monoclonalMGM protects CD4/ T cells from HIV-1 infected
antibody specific for gp120 and gp160. As shown in Fig.patients from apoptosis
4A, after 24 h of infection, the gp160 precursor was visible
in all the samples and MGM did not have any effect onThe data presented above suggested that MGM inter-
feres with HIV-1 replication in in vitro systems using hu- the amount of gp160. Only trace amounts of gp120 were
detected in the untreated sample and none in the MGM-man leukemic T cells Jurkat and MT2 and a laboratory
isolate of HIV-1. To test the activity of MGM against clini- treated ones. After 48 h, gp120 was already clearly pres-
ent in the control sample, whereas its formation wascal isolates of HIV-1, PBMCs from a normal donor were
stimulated with PHA and IL-2 and 48 h later were infected completely inhibited in the presence of 30 and 50 mM
MGM. These data suggest that, as expected, MGM inhib-with the HIV-1 primary isolate 1990 at a m.o.i. of 0.001.
The infected cells were cultured in the presence of differ- its the processing of HIV-1 gp160. Interestingly, after 48
h the amount of gp160 in MGM-treated samples wereent amounts of MGM and the release of p24 antigen to
the culture supernatant was measured to estimate viral also diminished, by up to 52% at 50 mM. To further evalu-
ate the effect of MGM on gp160 proteolytic processingreplication. As shown in Fig. 3A, MGM had a strong
inhibitory effect on the replication of the primary isolate and to determine whether it had any effect on the degra-
dation rate of gp160, a pulse–chase experiment wasof HIV-1. Thus, at 5 mM MGM inhibited by more than 98%
(636 vs 39384 pg/ml) the production of p24 at day 13, performed. To this end, MT2 cells were infected at a
m.o.i. of 2 with the viral isolate pNL and 48 h later wereand at 25 mM p24 was undetectable. In addition to the
effect on primary HIV-1 isolates, we analyzed whether labeled with [35S]methionine for 1 h. The labeled proteins
were then chased for the indicated times (Fig. 4B) andMGM protected T cells from AIDS patients from the cyto-
pathic effects of HIV-1 replication. To this end, PBMCs the cells were lysed and immunoprecipitated with a poly-
clonal anti-HIV antiserum. As shown in Fig. 4B, whereasfrom a seropositive patient with an initial 22% CD4/ popu-
lation were stimulated with PHA and IL-2 in the presence 44% of gp160 was converted to gp120 after a 2-h chase
in untreated cells, in the presence of MGM gp120 wasof different amounts of MGM, and the percentage of
CD4/ cells was evaluated at day 7. As shown in Fig. 3B, not detectable even after a chase time as long as 6 h.
By contrast, MGM did not have any effect on the amountsthe percentage of CD4/ cells in the untreated sample
was 15%, whereas in the presence of 1 mM MGM the of the gag gene products of 55 and 24 kDa that were
detected in the immunoprecipitates. These results con-percentage of CD4/ cells increased to 36% and reached
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FIG. 2. Inhibition of HIV-induced apoptosis by MGM. (A) Jurkat cells were infected with the S61p2 isolate at a multiplicity of 0.01 in the presence
of different concentrations of MGM and at day 14 the cell cycle was analyzed by propidium iodide staining. The percentage of cells with sub-G1
amounts of DNA is indicated in each panel. (B) Some cell samples from the above experiment were stained with the DNA-binding dye Hoechst
33258 and examined by fluorescence microscopy. Arrowheads indicate examples of fragmented, apoptotic nuclei.
firmed those of Fig. 4A and show that MGM inhibits shown in Fig. 5A, the envelope protein was distributed
in organelles that only partly colocalized with the trans-gp160 processing. Furthermore, Fig. 4B also shows that
MGM causes a rapid degradation of gp160. Indeed, after Golgi marker galactosyltransferase (Gal T). In other cells
not shown in the figure, gp120/gp160 was clearly de-the 1-h pulse, only 44% gp160 was present in MGM-
treated cells, compared to the untreated control, and after tected in the ER. However, in MGM-treated cells the
staining for gp160/120 was totally coincident with that ofa 2-h chase a further 55% of the initial gp160 was left.
The quantitation of these results is shown in Fig. 4C. the Gal T marker. These data show that in the presence
of MGM, gp160 is transported up to the trans-Golgi, sug-Interestingly, after the first degradation wave of gp160
that takes place during the first 2 h of chase in the pres- gesting that gp160 processing does not take place before
it reaches the trans-Golgi. Interestingly, although MGMence of MGM, gp160 seems to be stabilized. This result
suggests that in the presence of MGM newly synthesized caused the rapid degradation of unprocessed gp160
(Figs. 4B and 4C) this protein was not found in structuresgp160 is in part rapidly degraded, whereas the remaining
protein slowly reaches another compartment where it that could be reminiscent of lysosomes (Fig. 5A), sug-
gesting that either gp160 is degraded too rapidly to beremains undegraded.
The intracellular organelle where processing of gp160 detected in lysosomes or gp160 could be degraded in a
different compartment.to gp120 takes place is controversial. It has been pro-
posed that it takes place in the cis-Golgi network or even Because formation of syncytia depends on the interac-
tion of the envelope glycoprotein expressed on thein the ER (Stein et al., 1990). However, other authors have
shown that the gp160 processing enzymes reside in the plasma membrane of infected cells with CD4 from unin-
fected cells, it could be expected that the inhibition oftrans-Golgi network (Bedgood et al., 1992; Kantanen et
al., 1995). To determine whether the inhibition of gp160 gp160 processing by MGM resulted in a diminished for-
mation of syncytia. Indeed, no syncytia were observedprocessing by MGM could be the result of an altered
intracellular distribution, CD4/ HeLa cells were infected in CD4/ HeLa cells (not shown) nor in MT2 cells (Fig.
5B) after a single round of HIV replication in the presencewith the pNL isolate of HIV in the presence or absence of
30 mM MGM and were fixed 48 h postinfection. Adherent of MGM.
The above results are consistent with the notion thatHeLa cells were used for this experiment instead of
lymphoblastoid T cell lines to facilitate the observation MGM could be inhibiting the last steps of the viral cycle,
i.e., the formation of new infectious viral particles. Toof intracellular organelles under the microscope. As
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initial multiplicities of infection. However, in experiments
involving a single round of replication, MGM did not af-
fect p24 antigen release, although it reduced consider-
ably the production of infectious virions. These results
suggested that MGM inhibited a late step in viral replica-
tion that was demonstrated to be the proteolytic pro-
cessing of the envelope protein precursor gp160. The
mechanism of action of MGM on HIV replication is in
agreement with the previously reported antiviral effects
(Alarco´n et al., 1984, 1988) and with its effect on the Golgi
apparatus (Bonay et al., 1996). Thus, MGM had been
previously shown to inhibit the replication of the enve-
loped viruses herpes simplex (HSV), vesicular stomatitis
virus, and Semliki Forest virus, although it was com-
pletely inactive against the naked polio viruses (Alarco´n
et al., 1984). Furthermore, we have shown that MGM
inhibited the complete glycosylation of HSV protein,
pointing to a mechanism of action based on inhibition
of cellular proteins involved in glycoprotein processing
(Alarco´n et al., 1988). More recently, we have shown that
MGM causes swelling of the trans-cisternae of the Golgi
apparatus and inhibits the last modification steps of cel-
lular glycoproteins that take place in that compartment
(Bonay et al., 1996). Although the molecular target of
MGM was not identified, it appeared to inhibit vesicular
transport of proteins from the medial- to the trans-Golgi
in an in vitro assay. In this paper we have shown that
MGM causes the rapid degradation of gp160 and gp160
is found in organelles that stain with the trans-Golgi
marker galactosyltransferase. Because gp160 is not pro-
cessed in the presence of MGM, it can be inferred that
gp160 processing takes place beyond the trans-Golgi
in agreement with previous data (Bedgood et al., 1992;
Kantanen et al., 1995) and not in cis-located compart-
ments as has also been suggested (Stein and Engleman,
1990).
FIG. 2—Continued The inhibition of syncytia formation by MGM after a
single replicative cycle is consequent with its effect on
gp160 processing since formation of syncytia is known toverify this point, the supernatant from the experiment
depend on the cell surface expression of gp120. Indeed,shown in Fig. 4A was titrated on a cytopatic effect assay.
mutants of HIV-1 in the gp160 cleavage sequence areAs shown in Table 1, MGM reduced the production of
devoid of fusion activity (McCune et al., 1988). On theinfectious viruses below detection even though the re-
other hand, soluble and membrane-bound gp120 arelease of viral p24 antigen to the supernatant was unaf-
thought to cause apoptosis after binding to CD4 in unin-fected. These results suggest that MGM inhibits viral
fected T cells (Banda et al., 1992). This could be a majorspreading by preventing cell to cell transmission through
mechanism for depleting the number of CD4/ lympho-the formation of syncytia and virus to cell transmission
cytes beyond the number of infected cells. Perhaps theby inhibiting the release of infectious virions.
inhibition of gp120 formation by MGM could explain the
recovery of the number of CD4/ T cells in cultures of
DISCUSSION
peripheral blood lymphocytes from seropositive patients.
The overall effect of MGM on the HIV cycle seems toWe have shown in this paper that MGM strongly inhib-
be the inhibition of viral propagation by two possibleited the replication of HIV-1 isolates in human T cell lines,
mechanisms: fusion of infected cells with noninfectedreducing the production of p24 antigen, the formation of
syncytia, and apoptosis, in experiments performed at low cells and spreading of free virus from one cell to another.
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FIG. 3. Effect of MGM on replication of primary isolates of HIV-1. (A) PHA blasts from a normal donor were infected with clinical isolate 1990 of
HIV-1 at a m.o.i. of 0.001 and the release of p24 antigen to the culture supernatant was evaluated at the indicated times. Cell cultures were
maintained in the continuous presence of 5 mM (closed circles), 15 mM (closed triangles), 25 mM MGM (closed squares), or without drug (open
circles). (B) PBMC from a HIV-1 seropositive donor were cultured with PHA and IL-2 in the presence of different concentrations of MGM. After 7
days, the percentage of CD4/ cells was estimated by flow cytofluorimetry after staining with a CD4-specific antibody and it is indicated in each
panel. An irrelevant, isotype-matched monoclonal antibody (NMS) was used as a negative control. (C) The percentage of cells in apoptosis, estimated
by cell cycle analysis, is indicated in each panel.
MGM blocked formation of syncytia and reduced the pro- to the plasma membrane and inhibits HIV replication
(Dewar et al., 1989). Like MGM, monensin also inhibitedduction of infectious virions.
Other inhibitors that affect processing or maturation of processing of gp160 and reduced formation of syncytia.
By contrast, glycoprotein processing inhibitors as N-butylthe HIV envelope protein have been described. Monensin
inhibits vesicular transport at several stages from the ER deoxynojirimycin (N-butyl DNJ) act by preventing a postre-
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FIG. 4. Proteolytic processing of the envelope protein in the presence of MGM. (A) Western blot of total cell lysates from MT2 cells infected with
HIV-1 pNL isolate at a multiplicity of infection of 2.5 TCID50/cell and collected 24 and 48 h after infection. MGM was added 2 h after infection when
the viral inoculus was removed and maintained thereafter. The membrane was probed with an anti-gp160/gp120 specific antibody. (B) Pulse–chase
experiment showing the conversion of gp160 to gp120. MT2 cells were infected with HIV-1 pNL isolate at a m.o.i. of 2, 50 mM MGM was added
to half of the cultures, and 48 h later they were labeled with [35S]methionine for 1 h and chased for the indicated times. The envelope proteins
were immunoprecipitated with a human anti-HIV-1 antiserum. The positions of the gp160 and gp120 envelope proteins as well as of the 55- and
24-kDa gag products are indicated with arrows. (C) Quantitation of gp160 levels in MGM-treated (closed circles) and untreated cells (open circles).
The protein bands corresponded to gp160 and gp120 from B were quantitated in the phosphorimager and expressed as percentage of the gp160
plus gp120 protein remaining after each chase time.
ceptor binding step rather than by inhibiting gp120 forma- Although MGM’s target appears to be cellular and acts
by inhibiting the last steps of glycoprotein maturation, ittion (Karpas et al., 1988; Fleet et al., 1988). Interestingly,
although most glycoprotein processing or trimming inhibi- is not toxic to cells. Several cell lines have been grown
in the presence of 50 mM MGM for long periods of timetors were too toxic to cells, N-butyl DNJ inhibited HIV repli-
cation at concentrations below any detectable toxicity. (up to 6 weeks) without appreciable losses in their viability
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FIG. 5. Intracellular localization of HIV-1 envelope proteins in the presence of MGM. (A) Intracellular localization of the envelope protein. CD4/
HeLa cells were infected with HIV-1 pNL isolate at a multiplicity of 1 TCID50/cell and treated with or without MGM. Forty-eight hours later cells
were fixed and double-stained with a mouse monoclonal anti-gp160/gp120 antibody and a rabbit polyclonal anti-galactosyltransferase (Gal T)
followed by a Texas red-labeled anti-mouse Ig antibody and a FITC-labeled anti-rabbit Ig antibody. (B) Formation of syncytia. MT2 cells were infected
at a multiplicity of 2.5 TCID50/cell in the presence of the indicated concentrations of MGM and 48 h later nuclei were stained with propidium iodide.
Cells were examined by phase contrast and fluorescence microscopy. A syncytium in the untreated sample that contains multiple apoptotic nuclei
is shown.
or in their proliferative capability. These cells include the administered in a single intraperitoneal dose and of 5000
mg/kg when administered orally (Weinstein et al., 1972).human T cell line Jurkat as well as HeLa, COS, and NRK
cells. In addition, MGM’s toxicity has been measured on Therefore, the toxicity of MGM is in the range of widely
used antibiotics such as the closely related erythromycinprimary cells through its effect on anti-CD3 induced prolif-
eration of human PBMC, showing no significative inhibi- (LD50 i.p. in mice: 490 mg/kg (Umezawa, 1978)).
Interestingly, MGM inhibited HIV replication at dosestory effects up to 50 mM (San Jose´ and Alarco´n, unpub-
lished results). The toxicity of MGM in mice has been (1–15 mM) that lacked any measurable effect on Golgi’s
morphology. Thus, although MGM inhibits cellular glyco-previously determined, with a LD50 of 270 mg/kg when
TABLE 1
Infectious Virus Production in One Single Replicative Cycle in the Presence of MGM
24 h p.i 48 h p.i
MGM (mM) p24 (pg/ml)a TCID50/mlb p24 (pg/ml)a TCID50/mlb
0 9,088 10 284,078 4.4 1 106
30 6,774 0 258,101 103
50 15,000 0 186,542 4 1 102
Note. MT2 cells were infected with HIV-1 (pNL isolate) at 2.5 m.o.i. in the presence of the indicated concentrations of MGM and at 24 and 48 h
postinfection the supernatant was collected to evaluate the release of viral p24 antigen and of infectious virus.
a The supernatant from the equivalent to 50,000 cells was titrated.
b TCID50/ml, tissue culture infectious dose 50 from the supernatant of the equivalent to 500,000 cells.
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a macrolide antibiotic that shows antiviral activity and blocks proteinprotein processing pathways, it appears to have a selec-
glycosylation. FEBS Lett. 231, 207–211.tive antiviral effect. This selectivity could be explained
Alarco´n, B., Ley, S. C., Sa´nchez-Madrid, F., Blumberg, R. S., Ju, S. T.,
perhaps by the use of alternative pathways of transport Fresno, M., and Terhorst, C. (1991). The CD3-g and CD3-d subunits of
by cellular proteins, which bypass the trans-Golgi block- the T cell antigen receptor can be expressed within distinct functional
TCR/CD3 complexes. EMBO J. 10, 903–912.ade produced by MGM, that would not be available to
Banda, N. K., Bernier, J., Kurahara, D. K., Kurrle, R., Raigwood, N., Sekaly,the HIV-1 envelope proteins.
R. P., and Finkel, T. H. (1992). Crosslinking CD4 by human immunode-The prompt generation and selection of HIV strains
ficiency virus gp120 primes T cells for activation-induced apoptosis.
resistant to transcriptase inhibitors such as AZT are the J. Exp. Med. 176, 1099–1106.
major drawbacks in the clinical treatment of AIDS pa- Bedgood, R. M., and Stallcup, M. R. (1992). A novel intermediate in
processing of murine leukemia virus envelope glycoproteins: Proteo-tients. The combined therapy with non-cross-reactive
lytic cleavage in the late Golgi region. J. Biol. Chem. 267, 7060–7065.transcriptase inhibitors or with transcriptase inhibitors
Berger, E. G., Aegerter, E., Mandel, T., and Hauri, H. P. (1986). Mono-and protease inhibitors will make the appearance of re-
clonal antibodies to soluble, human milk galactosyltransferase (lac-
sistant strains of viruses less likely. However, the high tose synthase A protein). Carbohydr. Res. 149, 23–33.
mutation rate of HIV and the selective pressure imposed Bonay, P., Munro, S., Fresno, M., and Alarco´n, B. (1996). Intra-Golgi
transport inhibition by megalomycin. J. Biol. Chem. 271, 3719–3726.by the antiviral agents have already resulted in the devel-
Chesebro, B., and Wehrly, K. (1988). Development of a sensitive quanti-opment of multidrug-resistant strains (Collier et al., 1996;
tative focal assay for human immunodeficiency virus infectivity. J.Jacobsen et al., 1996). On the other hand, the generation
Virol. 62, 3779–3788.
of MGM-resistant strains of HIV is highly unlikely be- Collier, A. C., Coombs, R. W., Schoenfeld, D. A., Basset, R. L., Timpone,
cause MGM’s molecular target is host cell encoded and J., Baruch, A., Jones, M., Facey, K., Whitacre, C., McAuliffe, V. J., Fried-
man, H. M., Merigan, T. C., Reichman, R. C., Hooper, C., and Corey,therefore MGM would not put a selective pressure on
L. (1996). Treatment of human immunodeficiency virus infection withviruses that, for instance, do not bind the drug. In addi-
saquinavir, zidovudine and zalcitabine. N. Engl. J. Med. 334, 1011–tion, it is difficult to imagine the emergence of resistant
1017.
viruses not requiring proteolytic processing of gp160 for Dewar, R. L., Vasudevachari, M. B., Natarajan, V., and Salzman, J. P.
the production of fully infectious viruses. (1989). Biosynthesis and processing of human immunodeficiency
virus type I envelope glycoproteins: Effects of monensin on glycosyla-In summary, our results show that MGM inhibits repli-
tion and transport. J. Virol. 63, 2452–2456.cation of laboratory and clinical isolates of HIV-1 in T
Fleet, G. W., Karpas, A., Dwek, R. A., Fellows, L. E., Tyms, A. S., Peturs-cells and protects CD4/ T cells of seropositive patients
son, S., Namgoong, S. K., Ramsden, N. G., Smith, P. W., Son, J. C.,
from HIV-induced cytotoxicity in in vitro cultures. Further- Wilson, F., Witty, D. R., Jacob, G. S., and Rademacher, T. W. (1988).
more, MGM is shown to act by preventing the formation Inhibition of HIV replication by amino-sugar derivatives. FEBS Lett.
237, 128–132.of syncytia and infectious virions, probably due to an
Gruters, R. A., Neefjes, J. J., Tersmette, M., de Goede, R. E. Y., Tulp, A.,inhibition of the gp160 to gp120 processing. Finally, de-
Huisman, H. G., Miedema, F., and Ploegh, H. L. (1987). Interferencespite the previously reported effect of MGM on the trans-
with HIV-induced syncytium formation and viral infectivity by inhibi-
port of cellular proteins through the trans-Golgi, its low tors of trimming glucosidase. Nature 330, 74–77.
toxicity to cells allows optimism about its potential thera- Guo, H. G., Veronese, F. M., Tschachler, E., Pal, R., Kalyanaraman, V. S.,
Gallo, R. C., and Reitz, M. S., Jr. (1990). Characterization of an HIV-1peutic use.
point mutation blocked the envelope glycoprotein cleavage. Virology
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